BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Allergy Therapeutics plc Preliminary Results for the Year Ended 30 June 2011


9/19/2011 10:11:43 AM

19 September 2011 -- Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines announces preliminary results for the year ended 30 June 2011.

Highlights

- FDA to lift clinical hold on INDs for MATA-MPL© products subject to submission of agreed protocols

- Partnering process initiated to exploit significant US market opportunity

- 10 Marketing Authorisation Applications filed in Germany

- Pollinex Quattro grass filed in Switzerland

- Teomed AG acquisition in Switzerland fully integrated and beginning to deliver

- Netherlands subsidiary established and operating successfully

- Full-year revenue up 2% to £42 million (2010: £41 million); revenue up 5% at constant currency to £43 million

- Pollinex Quattro revenue up 2% at constant currency to £22 million (2010: £21 million)

- Number of in-licensing deals signed leveraging sales infrastructure

- PQ grass dossier report received from Germany’s PEI, response to be submitted November 2011

- EBITDA £1.8 million (2010: £2.9 million); adjusted EBITDA pre FX hedge fair valuation impact £2.6 million (2010: £2.9 million)

- Cost reduction plan executed and headcount reduced by 10%

Post reporting period events

- Initial roll-out of Emerging Market strategy with supplies to Latin America (August 2011)

- Anapen® distribution agreement extended to include UK and Ireland (September 2011)

Manuel Llobet, Chief Executive of Allergy Therapeutics, added:

“Allergy Therapeutics has made significant progress towards its goal to become one of the top 3 immunotherapy companies in the world and a leader in the subcutaneous segment of the market.

“During the year, we achieved important regulatory milestones including discussions with the FDA to resume US development of Pollinex Quattro and feedback from the PEI, the German regulatory body, for the registration of Pollinex Quattro Complete. Pollinex Quattro could be the first registered subcutaneous vaccine available to allergy sufferers in the US, and could also become the first injectable vaccine registered under the new European regulatory requirements.

“We remained profitable at an EBITDA level, despite a difficult environment in Germany, currently our largest market. This reflects a number of measures implemented to improve efficiency and reduce costs, which we expect will also benefit our performance in the current year. Transforming Allergy Treatment 2

“We have made good progress with our Emerging Markets strategy, introducing our own products in Latin America and licensing in products to improve our portfolio. We have established a subsidiary in Argentina and plans are already in place for additional distribution agreements in other key countries.

“By leveraging our established infrastructure in Europe and extending our presence into new markets, we are confident of improving profitability going forward and creating a sustainably profitable company.”

For further information

Allergy Therapeutics +44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities +44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics +44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES